BiotechTube

telmisartan/amlodipine 40/5mg + YH22162 40/5/12.5 mg + telmisartan/amlodipine 80/5mg + YH22162 80/5/25 mg + telmisartan/amlodipine 40/5mg placebo + YH22162 40/5/12.5 mg placebo + telmisartan/amlodipine 80/5mg placebo + YH22162 80/5/25 mg placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertension

Conditions

Hypertension

Trial Timeline

Dec 1, 2015 → Dec 1, 2016

NCT ID
NCT02620163

About telmisartan/amlodipine 40/5mg + YH22162 40/5/12.5 mg + telmisartan/amlodipine 80/5mg + YH22162 80/5/25 mg + telmisartan/amlodipine 40/5mg placebo + YH22162 40/5/12.5 mg placebo + telmisartan/amlodipine 80/5mg placebo + YH22162 80/5/25 mg placebo

telmisartan/amlodipine 40/5mg + YH22162 40/5/12.5 mg + telmisartan/amlodipine 80/5mg + YH22162 80/5/25 mg + telmisartan/amlodipine 40/5mg placebo + YH22162 40/5/12.5 mg placebo + telmisartan/amlodipine 80/5mg placebo + YH22162 80/5/25 mg placebo is a phase 3 stage product being developed by Yuhan for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02620163. Target conditions include Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Hypertension were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅Amlodipine + ValsartanYuhanApproved
✅Duowell® + TelmisartanYuhanApproved
✅Olmesartan medoxomil + Losartan potassium + AtenololDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + PlaceboDaiichi SankyoApproved
✅olmesartan medoxomil and a CCB + olmesartan medoxomil and a diureticDaiichi SankyoApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02620163Phase 3Completed

Competing Products

20 competing products in Hypertension

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
L04RD1 + L04TD3CelltrionPhase 1
29
Azilsartan MedoxomilCelltrionPre-clinical
26
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
40
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
47
Telmisartan + Amlodipine + ChlorthalidoneYuhanPhase 1
29
Temisartan/Amlodipine+Rosuvastatin + YHP1604YuhanPhase 1
29
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+RosuvastatinYuhanPhase 3
40
Amlodipine + ValsartanYuhanApproved
43
Duowell® + TelmisartanYuhanApproved
43
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
YH22189 + Twynsta 80/10mg + Crestor 20mgYuhanPhase 1
21
OM 40 + OM/HCTZ 40/12.5Daiichi SankyoPhase 3
40